Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages

  Kanda, Mitsuro ^a   Sadakari, Yoshihiko ^a   Borges, Michael ^a   Topazian, Mark ^b   Farrell, James ^c   Syngal, Sapna ^e   Lee, Jeffrey ^d   Kamel, Ihab ^a   Lennon, Anne Marie ^a   Knight, Spencer ^a   Fujiwara, Sho ^a   Hruban, Ralph H ^a   Canto, Marcia Irene ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MAYO CLINIC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Diagnostic; Early detection; Tumor

Indexed keywords

PROTEIN P53; SECRETIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DUODENUM; DYSPLASIA; FEMALE; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MUTANT; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS JUICE; PRECURSOR; PREVALENCE; PYROSEQUENCING; TUMOR INVASION;

EID: 84878150670     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.016     Document Type: Article

References (31)

1. Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009, 6:699-708.
2. Goggins M. Markers of pancreatic cancer: working toward early detection. Clin Cancer Res 2011, 17:635-637.
3. Shi C., Hruban R.H. Intraductal papillary mucinous neoplasm. Hum Pathol 2012, 43:1-16.
4. de Jong K., Nio C.Y., Hermans J.J., et al. High prevalence of pancreatic cysts detected by screening magnetic resonance imaging examinations. Clin Gastroenterol Hepatol 2010, 8:806-811.
5. Canto M.I., Hruban R.H., Fishman E.K., et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012, 142:796-804.
6. Ludwig E., Olson S.H., Bayuga S., et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011, 106:946-954.
7. Verna E.C., Hwang C., Stevens P.D., et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010, 16:5028-5037.
8. Langer P., Kann P.H., Fendrich V., et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009, 58:1410-1418.
9. Canto M.I., Goggins M., Hruban R.H., et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006, 4:766-781.
10. Canto M.I., Goggins M., Yeo C.J., et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004, 2:606-621.
11. Poley J.W., Kluijt I., Gouma D.J., et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009, 104:2175-2181.
12. Brentnall T.A., Bronner M.P., Byrd D.R., et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999, 131:247-255.
13. Klein A.P., Brune K.A., Petersen G.M., et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004, 64:2634-2638.
14. Hruban R.H., Maitra A., Goggins M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008, 1:306-316.
15. Shi C., Klein A.P., Goggins M., et al. Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009, 15:7737-7743.
16. Brune K., Abe T., Canto M., et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 2006, 30:1067-1076.
17. Yan L., McFaul C., Howes N., et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005, 128:2124-2130.
18. Löhr M., Müller P., Mora J., et al. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc 2001, 53:734-743.
19. Kanda M., Knight S., Topazian M., et al. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2012 Sept 17, [Epub ahead of print].
20. Redston M.S., Caldas C., Seymour A.B., et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994, 54:3025-3033.
21. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
22. Brune K., Hong S.M., Li A., et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 2008, 17:3536-3542.
23. Hruban R.H., Goggins M., Parsons J., et al. Progression model for pancreatic cancer. Clin Cancer Res 2000, 6:2969-2972.
24. Kanda M., Matthaei H., Wu J., et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012, 142:730-733.
25. Wilentz R.E., Iacobuzio-Donahue C.A., Argani P., et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-2006.
26. Leary R.J., Kinde I., Diehl F., et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010, 2. 20ra14.
27. Yamaguchi Y., Watanabe H., Yrdiran S., et al. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res 1999, 5:1147-1153.
28. Kaino M., Kondoh S., Okita S., et al. Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors. Pancreas 1999, 18:294-299.
29. Ohtsubo K., Watanabe H., Yao F., et al. Preproenkephalin hypermethylation in the pure pancreatic juice compared with p53 mutation in the diagnosis of pancreatic carcinoma. J Gastroenterol 2006, 41:791-797.
30. Tanaka M., Fernández-del Castillo C., Adsay V., et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012, 12:183-197.
31. Haeno H., Gonen M., Davis M.B., et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012, 148:362-375.